|
|
Latest oncology clinical development updates
Monday, February 09, 2026
|
|
|
|
|
OTW News Highlights this week
|
|
|
|
|
|
|
|
|
"This additional approval for Jaypirca, based on BRUIN CLL-313, marks a significant step forward, expanding its potential to reach more patients who may benefit – this time as an initial treatment for certain previously untreated patients with CLL or SLL," said Jacob Van Naarden, executive vice president and president of Lilly Oncology. "This milestone underscores Jaypirca's versatility in the CLL …
|
|
|
|
|
|
|
|
Mr Johnny Cheng, Acting Chief Executive Officer and Chief Financial Officer of HUTCHMED, said: “This filing is an important step toward potentially bringing ORPATHYS® plus TAGRISSO® to patients in the US, after its approval in China based on the SACHI Phase III trial. The success of the global SAFFRON Phase III trial reflects the long-standing collaboration between HUTCHMED and AstraZeneca …
|
|
|
|
|
|
|
|
“We believe the FDA Fast Track designation, an FDA-aligned global Phase 3 strategy, and funding to support China-generated clinical data would meaningfully strengthen our ability to advance Plinabulin and DUBLIN-4 toward the trial’s next major clinical milestone—the prespecified interim analysis at 221 PFS events,” said Min Qiu, CEO of BeyondSpring. “Fast Track designation underscores the significant unmet medical need for …
|
|
|
|
|
|
|
|
“We are proud to see the peer-reviewed results from the VIRAGE trial published in Nature Medicine and made available to the entire scientific community,” said Manel Cascalló, PhD, General Director of Theriva Biologics S.L. and co-author of the article. “As elaborated in the publication, improved overall survival, progression free survival, and duration of response were observed in metastatic pancreatic cancer …
|
|
|
|
|
|
|
|
“The positive topline results of the Phase 3 AZTOUND trial support the potential of an all-oral regimen of azacitidine and cedazuridine to meet the treatment needs of patients with MDS and CMML without the time and treatment burden associated with parenteral therapies,” said Harold Keer, MD, PhD, Chief Medical Officer, Taiho Oncology. “We look forward to pursuing regulatory approval of …
|
|
|
|
|
|
|
|
“From the beginning, our vision has been to translate this breakthrough science into therapies that can make a profound difference for people impacted by cancer,” said co-founder Robbie Majzner, M.D., of the Dana-Farber Cancer Institute and Harvard Medical School. “Bringing in leaders with the experience, commitment and passion to advance our technology and execute at scale gives me tremendous confidence …
|
|
|
|
|
|
|
|
Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences, stated, "Ovarian cancer remains one of the deadliest cancers affecting women, and patients with recurrent disease face limited treatment options and poor outcomes. While this Phase 1 study is primarily designed to evaluate safety, we are highly encouraged that multiple patients have surpassed one year of survival following treatment, with one …
|
|
|
|
|
|
|
|
“Gilead’s decision to extend the research term for this program reflects our longstanding commitment to productive collaborations, the outstanding dedication of our research teams, and the potential of Nurix’s targeted protein degradation platform to generate novel medicines against therapeutically important targets,” said Gwenn M. Hansen, Ph.D., chief scientific officer of Nurix. “Our collaboration has already advanced GS-6791, an oral IRAK4 …
|
|
|
|
|
|
|
|
"We are pleased to collaborate with Roche to advance the development of UI-102 for patients with hard-to-treat cancers," said Masato Kishida, Chief Executive Officer of United Immunity. "In preclinical studies, UI-102 demonstrated enhanced anti-tumor activity in combination with immune checkpoint inhibitors compared with checkpoint inhibitor monotherapy in tumor models that were otherwise resistant to checkpoint blockade. We believe these findings …
|
|
|
|
|
|
|
|
Author
Managing Editors
Social Media Managers
|
|
|
|
|
|
Disclaimer: The OTW team takes care to share authentic information. In case of any discrepancies please write to newsletter@onco-this-week.com. Our website is an aggregator for open-source oncology news. The information on our website is provided without any representations or warranties. OTW is a part of RLS Consultants, which is a global consulting and training firm focusing exclusively on the healthcare and life sciences industries. RLS is a leading provider of opportunity assessment services, utilizing its comprehensive expertise in strategic market research, forecasting, and modeling, as well as pricing and market access to facilitate commercial assessments. RLS does not have any influence on any news reported on OTW. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of RLS. The content on our website is intended strictly for news and information purposes only and should not be treated as a substitute for medical advice, diagnosis, or treatment. News shared on OTW should not be utilized in real-world analytic products as they are based only on limited and dated open-source information.
|
|
|
|
|
|
|
